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Abstract
Objective. To identify the parameters associated with self-reported diagnostic delay (DD) in axial spondyloarthritis
(axSpA) patients across Europe.
Methods. Data from 2652 patients from 13 countries who participated in the European Map of Axial Spondyloarthritis
(EMAS) were collected through an online survey (2017–2018). DD was calculated as the difference between age at diag-
nosis and age at symptom onset reported by participants. Associations between DD and sociodemographic characteris-
tics, as well as disease-related factors were explored through univariable and multivariable linear regression analysis.
Results. Average DD was 7.4 (8.4) years with a variation between countries. The variables associated with longer DD in
the final multivariable regression model were: younger age at symptom onset (b ¼ 0.26; 95% CI: 0.28, 0.23), female
gender (b¼1.34; 95% CI: 0.73, 1.96) and higher number of health-care professionals (HCPs) seen before diagnosis
(b¼1.19; 95% CI: 0.95, 1.43). There was a significant interaction between the female gender and the number of HCPs
seen before diagnosis. A substantial variation of the DD across European countries was observed.
Conclusion. In this sample of axSpA patients, average DD was greater than 7 years. Younger age at symptom onset,
female gender, higher number of HCPs seen before diagnosis, and being diagnosed by rheumatologist were the param-
eters associated with a longer DD in axSpA. These findings indicate a need for continuing efforts dedicated to recogni-
tion of patients with a high probability of axSpA on the level of non-rheumatology specialists and facilitating referral to
a rheumatologist for timely diagnosis.
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Introduction
Early diagnosis of axial spondyloarthritis (axSpA), an in-
flammatory disease characterized by an insidious progres-
sion that can cause irreversible structural damage to the
spine, is crucial for initiation of optimal treatments that
may result in a more favourable prognosis for patients [1,
2]. However, despite extensive research on the illness,
diagnostic delay (DD) in axSpA remains high and in fact,
is one of the longest among rheumatic diseases [3].
During the period in which axSpA is not accurately
identified, patients are forced to cope not only with the
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. Diagnostic delay in axial spondyloarthritis patients is on average greater than 7 years.
. Compared with men, women with axial spondyloarthritis are diagnosed 2 years later.
. Younger age at symptom onset, female gender, visit to HCPs, and being diagnosed by a rheumatologist are
strongly associated with axSpA delayed diagnosis.
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insidious nature of axSpA onset [4], but also with the
anxiety of uncertainty about their diagnosis [5]. Many
patients may undergo unnecessary and/or invasive test-
ing and receive inadequate treatment for their condition
[6], which may ultimately lead to poorer prognostic out-
comes [7].
In order to establish accurate clinical guidelines that
enable early diagnosis, identification of the factors asso-
ciated with its delay is key. Various studies have found
different factors associated with increased DD, including
female gender [8–10], younger age at symptom onset
[9], HLA-B27 negativity [7, 9, 11], presence of enthesitis
or entheseal pain [7, 12], no family history of SpA [10],
older age at diagnosis [12], absence of peripheral arth-
ritis or dactylitis [12], and presence of psoriasis [9].
However, to date, these findings have not been repli-
cated in an international setting.
The objective of the present study was to evaluate DD
and identify its associated parameters in a large and




EMAS was a cross-sectional online survey of patients with
a self-reported diagnosis of axSpA encompassing 13
European countries: Austria, Belgium, France, Germany,
Italy, the Netherlands, Norway, Russia, Slovenia, Spain,
Sweden, Switzerland and the UK. The survey was adapted
from the Spanish Atlas of Axial Spondyloarthritis 2017 [13],
the results of which were added retrospectively to the
EMAS database. The methodology of the EMAS study is
described in detail elsewhere [14].
Working group
The EMAS project is a collaboration led by the Health &
Territory Research group of the University of Seville, Axial
Spondyloarthritis International Federation (ASIF), Novartis
Pharma AG and a steering committee composed of patient
research partners and internationally recognized rheumatol-
ogists, psychologists and researchers specialized in axSpA.
Patients
Participants were recruited between July 2017 and March
2018 by Ipsos SA (formerly GfK), a market research agency,
through their existing database of respondents. Some na-
tional patient advocacy groups (PAGs) also supported re-
cruitment by distributing the survey to their members in the
following countries: Austria, Italy, the Netherlands, Norway,
Russia, Slovenia, Spain, and Sweden (Fig. 1).
The inclusion criteria were: aged 18 years, residents
of an EMAS country, a self-reported clinician-provided
diagnosis of axSpA, including ankylosing spondylitis or
non-radiographic axSpA, and visit to a health-care pro-
fessional for axSpA in the 12 months prior to inclusion.
Instruments
The EMAS survey consisted of a patient questionnaire
administered online. The questionnaire included 108
items related to 12 different areas: sociodemographic
and anthropometric characteristics, disability assess-
ment, working life, daily life, lifestyle habits, diagnostic
journey, health-care utilization, treatment, comorbidities
(including extra-articular manifestations), psychological
distress/mental health, axSpA-specific outcomes, and
patient disease-related attitudes and treatment goals. All
variables collected for the EMAS survey were patient-
reported (see Supplementary Table S1, available at
Rheumatology online).
Diagnostic delay assessment
DD was calculated with self-reported data from the fol-
lowing two items of the EMAS survey: ‘Age at first
symptom onset (pain, inflammation, stiffness) associated
with Spondylitis/Spondyloarthritis’ and ‘Age at which
you were diagnosed with Spondylitis/Spondyloarthritis’.
The year of diagnosis was calculated by subtracting the
age of the patients at the time of the survey from the
age at the time of diagnosis.
Statistical analysis
In order to identify the associated parameters to DD,
only variables that could be present at the time of dis-
ease onset/diagnosis were assessed. The Mann–
Whitney test was used to evaluate the difference DD be-
tween variables with two categories: gender (male, fe-
male), occupation (manual worker, non-manual worker),
diagnosed by rheumatologist (yes, no), HLA-B27 (posi-
tive, negative), presence of psoriasis (yes, no), presence
of uveitis (yes, no), and presence of inflammatory bowel
disease (yes, no). Although the presence of family his-
tory of axSpA was collected in the EMAS survey, this
variable was not considered in the analysis because it
did not differentiate between patients who knew about
these cases before or after the time of their diagnosis.
The Kruskal-Wallis test was used to evaluate the differ-
ences in DD between variables with more than two cate-
gories (age at symptom onset, educational status).
Univariable and multivariable linear regression analysis
was used to evaluate the relationship between DD and
candidate variables (age at symptom onset, gender,
diagnosed by rheumatologist, number of HCPs seen be-
fore diagnosis, and country). In addition, we performed
an assessment of the interaction between the candidate
variables. Due to a significant interaction between the
number of HCPs seen before diagnosis and female gen-
der (see results below), we constructed an additional
model stratified by gender that included the following in-
dependent variables: age at symptom onset, being diag-
nosed by rheumatologist, number of HCPs seen before
diagnosis, and country. The factor country was intro-
duced as a dummy variable taking France (country with
the largest sample size and the DD close to the mean in
the entire sample) as a reference.
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The regression coefficients (b) and corresponding
95% CIs were reported. SPSS 26.0 version was used to
carry out the analysis.
Results
Of the 2846 EMAS participants, 2652 were included as
they provided information on both age at symptom onset
and age at diagnosis (Fig. 1). Mean age at symptom
onset was 26.6 (11.0), mean age at diagnosis was
34.1 (11.1), and resulting mean DD was 7.4 (8.4) years
(Table 1). DD was unevenly distributed among participat-
ing European countries, varying significantly from one to
another. The highest average reported DD was that of
Norway, followed by Spain, Slovenia and Sweden (from
10.6–7.6 years), while the countries with the lowest aver-
age were identified as the UK, Germany, Switzerland and
Belgium (from 2.6–3.6 years) in that order (Fig. 2).
In the bivariate analysis, a longer DD was associated
with younger age at symptom onset, female gender, and
diagnosis made by a rheumatologist (Table 2), which were
also evident in the univariable regression analysis (Table 3).
In addition, a higher number of HCPs visited before diag-
nosis showed an association with a longer DD (Table 2).
In the multivariable model 1, a longer DD was associated
with younger age at symptom onset (b ¼ 0.26; 95% CI:
0.28, 0.23), with female gender (b¼1.34; 95% CI: 0.73,
FIG. 1 Sample selection flow chart
PAG: Patient Advisory Group; GfK: market research agency currently known as Ipsos Group S.A.; EMAS: European
Map of Axial Spondyloarthritis.
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1.96) and with the number of HCPs seen before diagnosis
(b¼1.19; 95% CI: 0.95, 1.43). Furthermore, in model 1
Norway, Spain and Sweden were associated with longer
DD using France as a reference (Table 3).
There was a significant interaction between gender
and the number of HCPs seen before diagnosis
(b¼0.56; 95% CI: 0.06, 1.05 for the interaction term),
therefore, we performed an analysis stratified by gender
(model 2). In this model, younger age at symptom onset
showed a stronger association with longer DD in females
(b¼ 0.32; 95% CI: 0.35, 0.28) than males (b¼
0.18; 95% CI: 0.21, 0.14). Furthermore, DD was
more strongly associated with a higher number of HCPs
seen before diagnosis in females (b¼1.31; 95% CI 1.00,
1.62) than males (b¼ 0.92; 95% CI: 0.56, 1.29) (Table 3).
Discussion
In this large sample of axSpA patients from 13 different
European countries, the average DD was more than 7
years. This is compatible with the recent data obtained
on a national level in the UK [15] and Germany [9]. For
axSpA patients, whose symptoms typically start in their
mid-twenties [16], these are 7 years of intermittent pain,
inflammation, fatigue, numerous medical tests, unneces-
sary visits to specialists, uncertainty, anxiety, depression
and impact on quality of life [2, 6]. Moreover, as axSpA
appears in a life stage when patients are supposed to
be entering the labour market, the negative consequen-
ces it can have over the course of a lifetime may inter-
fere with an individual’s ability to reach their full
potential. As such, early detection of axSpA is critical
for mitigating the physical, psychological and social im-
pact of the disease.
The pan-European figure for DD is comparable to that
of other studies [10]. However, what this study adds is
the variability of DD among European countries. Our
understanding is that the DD reported by EMAS is rep-
resentative of the real-world situation of axSpA patients
in Europe, compared with the data collected by studies
relying exclusively on clinical records. In the EMAS
TABLE 1 Baseline characteristics of participants included in the diagnostic delay analysis (N¼ 2652, unless otherwise
specified)
Sociodemographic characteristics Mean (S.D.)/Median or n (%)
Age (years) 43.9 (12.2)/43.0
Female gender 1644 (62.0)
Educational level n¼2846 No school completed 28 (1.1)
Primary school 226 (8.5)
High school 1092 (41.2)
University 1306 (49.2)
Currently employed n¼2532 1369 (54.1)
Occupation n¼1174 Manual worker 175 (14.9)
Non-manual worker 999 (85.1)
Lifestyle habits
Current smoker n¼2651 858 (32.4)
BMI (kg/m2) 26.1 (5.4)/25.3
Patient organization member 1032 (38.9)
Clinical characteristics
Age at onset of first symptoms (years) 26.6 (11.0)/25.0
Age at diagnosis (years) 34.1 (11.1)/33.0
Diagnostic delay (years) 7.4 (8.4)/4.0
Disease duration since symptom onset (years) n¼2649 17.2 (12.3)/15.0
Positive family history of SpA n¼2186 851 (38.9)
Diagnosed by rheumatologist n¼2564 2023 (78.9)
Number of HCPs seen before diagnosis 2.7 (1.3)/3.0
HLA-B27 positivity n¼1744 1258 (72.1)
BASDAI (0–10) n¼2512 5.5 (2.0)/5.7
BASDAI 4 (0–10) n¼2512 1961 (78.1)
Presence of inflammatory bowel disease (ever) n¼1871 272 (14.5)
Presence of acute anterior uveitis (ever) n¼2402 454 (18.9)
GHQ-12 (0–12) n¼2565 4.9 (4.1)/4.0
GHQ-123 (0–12) n¼2565 1576 (61.4)
Global Limitation Index (0–54) n¼2652 20.2 (16.1)/17.0
Global Stiffness Index (3–12) n¼2585 7.7 (2.5)/8.0
NSAIDs intake (ever) n¼2091 1318 (63.0)
bDMARDs intake (ever) n¼2091 773 (37.0)
HLA-B27: human leucocyte antigen B27; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; GHQ-12: 12-item
General Health Questionnaire; bDMARDs: biologic disease-modifying anti-rheumatic drugs.
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FIG. 2 Distribution of diagnostic delay of axSpA across EMAS countries (N¼ 2652)
Circle area represents the relative sample size of their respective countries.
TABLE 2 Associations between sociodemographic and disease-related variables and diagnostic delay
Variable Diagnostic delay Mean (S.D.) P-value




Gender Male 6.1 (7.4) <0.001
Female 8.2 (8.9)
Education level No schooling completed 8.0 (10.7) 0.397
Primary school 7.6 (8.9)
High school 7.6 (8.4)
University 7.3 (8.3)
Occupation Manual worker 6.7 (8.3) 0.163
Non-manual worker 7.3 (8.4)
Diagnosed by rheumatologist Yes 7.9 (8.7) <0.001
No 5.7 (7.3)
Number of HCPs seen before diagnosis 0 6.5 (7.0) <0.001
1–2 5.2 (7.2)
3 or more 9.4 (9.0)
HLA-B27 Positive 8.3 (8.3) 0.775
Negative 8.7 (9.0)
Psoriasis (ever) Yes 8.2 (10.0) 0.516
No 7.4 (8.1)
Uveitis (ever) Yes 8.0 (8.3) 0.098
No 7.6 (8.4)
Inflammatory bowel disease (ever) Yes 7.7 (8.7) 0.944
No 7.5 (8.5)
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study, participants were recruited through patient panels
and patient organizations and, therefore, the resulting
sample included a variety of patients who do not neces-
sarily regularly attend health-care centres. This length of
DD of axSpA patients in Europe is unacceptable and un-
doubtedly impacts on many aspects of the health condi-
tion and life of the patient. Thus, solutions for its
reduction must be found urgently.
Several factors associated with a longer DD could be
identified. The association of the longer DD with young
age of symptom onset might look paradoxical at first
glance. However, the same factor was found recently to
be associated with longer DD in a nationwide study from
Germany [9]. Most likely, back pain in young adults is
often neglected or is not taken seriously enough to initi-
ate referral to a rheumatologist or a diagnostic process to
confirm or exclude an inflammatory nature of back pain.
We also found that the number of HCPs seen before
diagnosis and being diagnosed by a rheumatologist (as
opposed to general practitioners and other specialists)
are associated with a longer DD. Most probably,
patients who are diagnosed by a rheumatologist may
account for axSpA cases that are difficult to detect for
non-rheumatologists, therefore patients visit many non-
rheumatologist HCPs before presenting to a rheumatolo-
gist who finally makes or confirms the axSpA diagnosis.
Furthermore, we revealed that female axSpA patients
suffer from longer DD as compared with males even
when they present with similar symptoms—a fact that
has been shown in previous studies [8, 9, 17]. Longer
DD in females may be due to the fact that in women
with back pain, axSpA is often considered an unlikely
diagnosis that results in the referral to health-care pro-
fessionals other than rheumatologists. This could be
confirmed by a significant interaction between female
gender and number of HCPs seen before diagnosis
shown in the regression analysis. Furthermore, in our
gender-stratified model, we could show that in female
patients both the younger age at symptom onset and
the number of HCPs seen before diagnosis were more
strongly associated with higher DD than in male
patients. Data from research carried out in Spain sup-
ports this hypothesis. In this study, male and female
patients with similar symptoms of inflammatory back
pain attended a general practitioner, but only men were
referred to a specialized rheumatologist [5]. Reasons for
this phenomenon may be related to women presenting a
higher frequency of non-classical forms of axial spondy-
loarthritis, such as non-radiographic [18] or to their
increased frequency of comorbidity with other condi-
tions like fibromyalgia [19]. These issues may have led
to consideration of axSpA as a ‘male disease’ further
perpetuating the DD in women [8].
The country factor helps to control for the effect of
the other independent variables on the association with
DD, with Norway, Sweden and Spain being the
TABLE 3 Univariable and multivariable linear regression analysis of the association between diagnostic delay and candi-
date variables in patients with axial spondyloarthritis
Variables Ref. Univariable analysis Multivariable analysis
Model 1 (n 5 2563) Model 2
Male (n 5 972) Female (n 5 1590)
B 95% CI B 95% CI B 95% CI B 95% CI
Age at symptom onset, years – 0.29 0.32, 0.26 0.26 0.28, 0.23 0.18 0.21, 0.14 0.32 0.35, 0.28
Female gender Male 2.10 1.44, 2.76 1.34 0.73, 1.96 – – – –
Diagnosed by
rheumatologist, yes
No 2.12 1.32, 2.91 0.41 0.33, 1.15 0.34 0.66, 1.35 0.37 0.68, 1.41
Number of HCPs
seen before diagnosis
– 1.72 1.49, 1.96 1.19 0.95, 1.43 0.92 0.56, 1.29 1.31 1.00, 1.62
Country, Austria France 2.22 4.09, 0.35 0.44 1.37, 2.24 0.29 2.85, 2.28 1.23 1.27, 3.74
Country, Belgium 3.39 5.36, 1.41 1.74 3.61, 0.12 0.81 3.39, 1.76 2.63 5.28, 0.03
Country, Germany 4.28 6.22, 2.34 1.68 3.53, 0.17 1.78 4.20, 0.65 1.54 4.37, 1.29
Country, Italy 1.71 3.25, 0.17 0.03 1.39, 1.45 0.23 1.92, 2.38 0.10 1.99, 1.79
Country, Netherlands 0.08 1.69, 1.86 1.07 0.54, 2.68 2.78 0.40, 5.17 0.21 2.37, 1.95
Country, Norway 3.68 2.63, 4.73 2.78 1.88, 3.68 1.67 0.05, 3.29 3.24 2.15, 4.32
Country, Russia 0.06 1.27, 1.15 0.48 0.69, 1.66 1.70 0.09, 3.49 0.38 1.97, 1.21
Country, Slovenia 0.84 1.05, 2.72 1.27 0.45, 2.98 0.91 1.48, 3.30 1.87 0.57, 4.30
Country, Spain 1.58 0.67, 2.49 1.17 0.28, 2.07 1.64 0.19, 3.10 1.09 0.09, 2.27
Country, Sweden 0.61 1.46, 2.67 1.92 0.05, 3.80 2.43 0.54, 5.40 1.73 0.66, 4.13
Country, Switzerland 3.42 5.34, 1.50 0.72 2.52, 1.09 0.06 2.49, 2.36 1.67 4.34, 1.00
Country, United Kingdom 4.38  6.35, 2.41 1.71 3.62, 0.19 1.98 4.78, 0.83 1.19 3.74, 1.37
Dependent variable in all models: diagnostic delay in years. CI: confidence interval; HCP: health-care professional.
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countries associated with the highest DD. However, the
country factor should be interpreted with caution be-
cause countries are compared with a reference country
(France) that had the largest sample size and a mean
DD similar to the overall mean of our study.
As the results of our study show, Sweden, Spain, and
Norway present a greater DD. This could be due to the
fact that in these three countries the symptoms onset
appeared on average in the late 1990s (1998, 1996 and
1994). This is 10 years earlier than in other countries
such as Italy, Germany or the UK where patients
reported a more recent symptom onset. During this
period, knowledge about the disease has improved.
Furthermore, in Sweden, Spain and Norway the number
of visits to HCPs (2.2, 2.9 and 3.2) and the number of
tests performed (2.6, 2.8 and 2.4) before diagnosis were
higher, which could be due to application of inappropri-
ate diagnostic tests for axSpA.
In summary, as ASAS-EULAR management recom-
mendations state, early detection and diagnosis of
axSpA are paramount to its primary treatment goal,
which is to maximize long-term health, quality of life,
and prevent progressive structural damage [20].
Understanding that the number of HCPs visited before
diagnosis is strongly associated with DD, suggests that
both HCP education and effective referral practices are
key to decreasing DD in axSpA.
EMAS is the largest survey carried out to date for
axSpA patients, gathering 2846 respondents from 13
European countries. In this study, women and people
with university studies may seem over-represented.
Research methods for this study (online survey panel)
may have biased sampling towards female and highly
educated participants. However, EMAS sociodemo-
graphic characteristics (age and marital status) are in
line with what is published in other axSpA-related stud-
ies. The inclusion of information from a sample of axSpA
patients from 13 European countries has served to cap-
ture differences across the European continent, general-
ly ignored in previous published studies. The novel
focus in the EMAS study was to achieve a holistic ap-
proach using a questionnaire designed for patients, rely-
ing on data collected from the patient perspective.
Unlike many other studies that tend to rely heavily on
clinical records and patients presenting to rheumatolo-
gists, the EMAS survey allowed for the collection of
real-world data. Data collected in this way has repre-
sented people in different geographical locations, not
just urban, with different health lifestyles, and different
relationships with their healthcare system.
The EMAS study is not without limitations. First, the
survey relied on self-reported data, and did not attempt
to confirm participant diagnosis nor support participant
responses with clinician-reported assessments. As a re-
sult, lab markers of disease activity were not available,
and HLA-B27 status was reported for a relatively small
proportion of patients and could not be verified. The
same is also true for the classification status (radio-
graphic or non-radiographic), which cannot be verified;
therefore, we focused on the analysis of the entire
population.
In addition, information on the presence of extra-mus-
culoskeletal manifestations was gathered at the time of
the survey and was not restricted to the period before
diagnosis. Finally, the possibility of recall bias cannot be
ruled out for those variables referring to events that
occurred decades back in the patients’ lives, such as
the age at symptom onset—this is, however, true for
any study collecting symptom duration since this infor-
mation often cannot be verified.
Conclusion
In this large sample of axSpA patients from 13 different
European countries, the average DD was more than 7
years. Younger age at symptom onset, female gender,
higher number of HCPs seen before diagnosis, and
being diagnosed by a rheumatologist were factors asso-
ciated with a longer DD; there was a significant inter-
action between female gender and the number of HCPs
seen before diagnosis. HCP education and effective re-
ferral practices to a rheumatologist are key to decreas-
ing the DD in axSpA.
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